David Ashley
Overview:
Dr. Ashley's primary research focus is laboratory based, investigating the role of immunotherapy as a novel approach to the treatment of tumors of the central nervous system (CNS). Since beginning his appointment at the faculty level at Duke in August of 1995 his activities have centered on two main areas of investigation. The first involves both in vivo and in vitro studies of the use of molecular therapeutics to target a CNS tumor associated antigen. The second area of interest comprises a detailed analysis of the role of TGF beta, a protein messenger produced by tumors of the CNS, both in the pathogenesis of disease and as a possible target for immunotherapy.
In addition to his laboratory role Dr. Ashley is involved in the design and application of a variety of clinical research protocols in the treatment of children with malignant brain tumors.
In addition to his laboratory role Dr. Ashley is involved in the design and application of a variety of clinical research protocols in the treatment of children with malignant brain tumors.
Positions:
Rory David Deutsch Distinguished Professor of Neuro-Oncology
Neurosurgery
School of Medicine
Professor of Neurosurgery
Neurosurgery
School of Medicine
Professor of Medicine
Medicine, Medical Oncology
School of Medicine
Professor in Pathology
Pathology
School of Medicine
Professor in Pediatrics
Pediatrics, Hematology-Oncology
School of Medicine
Member of the Duke Cancer Institute
Duke Cancer Institute
School of Medicine
Education:
F.R.A.C.P. 1993
Royal Australasian College of Physicians (Australia)
M.B.B.S. 1994
University of Melbourne (Australia)
Ph.D. 1998
University of Melbourne (Australia)
Grants:
LGG-14C03: A Phase III study comparing two carboplatin containing regimens for children and young adults with previously untreated low grade glioma
Administered By
Duke Cancer Institute
Awarded By
Ann & Robert H Lurie Children's Hospital of Chicago
Role
Principal Investigator
Start Date
End Date
SJMB12: A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Administered By
Pediatrics, Hematology-Oncology
Awarded By
St. Jude Children's Research Hospital
Role
Principal Investigator
Start Date
End Date
NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEMPRIMITIVE NEURO-ECTODERMAL TUMORS:CLINICAL AND MOLECULAR RISK-TAILORED INTENSIVE AND COMPRESSED INDUCTION CHEMOTHERAPY FOLLOWED BY CONSOLIDATION WI
Administered By
Duke Cancer Institute
Awarded By
Research Institute at Nationwide Children's Hospital
Role
Principal Investigator
Start Date
End Date
Collaborative Network for Neuroooncology Clinical Trials (CONNECT)
Administered By
Duke Cancer Institute
Awarded By
Cincinnati Children's Hospital Medical Center
Role
Principal Investigator
Start Date
End Date
A Phase II study of Panobinostat in Paediatric, Adolescent and Young Adult Patients with Solid Tumours (ATRT)
Administered By
Duke Cancer Institute
Awarded By
Australian and New Zealand Children's Haematology/Oncology Group
Role
Principal Investigator
Start Date
End Date
Publications:
PHASE IB STUDY OF UNESBULIN (PTC596) IN CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)
Authors
Lazow, MA; Baxter, P; Stanek, J; Lane, A; Rodriguez, DP; Kumar, SS; Leach, JL; Mikael, L; Fuller, C; Boue, DR; Pierson, CR; Thomas, D; Breneman, J; Palmer, J; Li, X-N; Salloum, R; Ashley, D; de Blank, P; Hwang, E; Leary, SES; Plant, A; Crabtree, D; Wahba, M; Weetall, M; Baird, J; Leonard, J; Stewart, CF; Mardis, E; Fouladi, M; Drissi, R
MLA Citation
Lazow, Margot A., et al. “PHASE IB STUDY OF UNESBULIN (PTC596) IN CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT).” Neuro Oncology, vol. 24, 2022, pp. 36–36.
URI
https://scholars.duke.edu/individual/pub1534054
Source
wos-lite
Published In
Neuro Oncology
Volume
24
Published Date
Start Page
36
End Page
36
CHARACTERIZING THE LANDSCAPE OF STRUCTURAL VARIANTS IN ADAMANTINOMATOUS CRANIOPHARYNGIOMA
Authors
Jomaa, D; Khadka, P; Novikov, D; Condurat, AL; Tsai, JW; Dubois, F; Zhang, S; Zhou, K; Gold, R; Sousa, C; Vogelzang, J; Prince, E; Lu, S; Slivova, V; Otto, GW; Hereza, SC; Ashley, D; Cohen-Gadol, AA; Thompson, E; Beroukhim, R; Apps, J; Martinez-Barbera, JP; Hankinson, T; Bandopadhayay, P
MLA Citation
Jomaa, Danny, et al. “CHARACTERIZING THE LANDSCAPE OF STRUCTURAL VARIANTS IN ADAMANTINOMATOUS CRANIOPHARYNGIOMA.” Neuro Oncology, vol. 24, 2022, pp. 14–14.
URI
https://scholars.duke.edu/individual/pub1534383
Source
wos-lite
Published In
Neuro Oncology
Volume
24
Published Date
Start Page
14
End Page
14
A PHASE II STUDY OF CONTINUOUS LOW DOSE PANOBINOSTAT IN PAEDIATRIC PATIENTS WITH MALIGNANT RHABDOID TUMOURS AND ATYPICAL TERATOID RHABDOID TUMOURS
Authors
MLA Citation
Wood, Paul, et al. “A PHASE II STUDY OF CONTINUOUS LOW DOSE PANOBINOSTAT IN PAEDIATRIC PATIENTS WITH MALIGNANT RHABDOID TUMOURS AND ATYPICAL TERATOID RHABDOID TUMOURS.” Neuro Oncology, vol. 24, 2022, pp. 6–7.
URI
https://scholars.duke.edu/individual/pub1535007
Source
wos-lite
Published In
Neuro Oncology
Volume
24
Published Date
Start Page
6
End Page
7
RECONSTITUTION OF CGAS/STING PATHWAY VIA EPIGENETIC REPROGRAMMING LEADS TO ANTI-VIRAL INFLAMMATORY SIGNALING IN ATYPICAL TERATOID RHABDOID TUMORS (ATRTS)
Authors
Mangoli, A; Hariharan, S; Ashley, D; Fuller, R; Bowie, M; Briley, A; Brown, M; Hostettler, J
MLA Citation
Mangoli, Avani, et al. “RECONSTITUTION OF CGAS/STING PATHWAY VIA EPIGENETIC REPROGRAMMING LEADS TO ANTI-VIRAL INFLAMMATORY SIGNALING IN ATYPICAL TERATOID RHABDOID TUMORS (ATRTS).” Neuro Oncology, vol. 24, 2022, pp. 1–1.
URI
https://scholars.duke.edu/individual/pub1535025
Source
wos-lite
Published In
Neuro Oncology
Volume
24
Published Date
Start Page
1
End Page
1
cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma.
Median survival of patients with glioblastoma (GBM) treated with standard of care which consists of maximal safe resection of the contrast-enhancing portion of the tumor followed by radiation therapy with concomitant adjuvant temozolomide (TMZ) remains 15 months. The tumor microenvironment (TME) is known to contain immune suppressive myeloid cells with minimal effector T cell infiltration. Stimulator of interferon genes (STING) is an important activator of immune response and results in production of Type 1 interferon and antigen presentation by myeloid cells. This review will discuss important developments in STING agonists, potential biomarkers for STING response, and new combinatorial therapeutic approaches in gliomas.
Authors
Tripathi, S; Najem, H; Mahajan, AS; Zhang, P; Low, JT; Stegh, AH; Curran, MA; Ashley, DM; James, CD; Heimberger, AB
MLA Citation
Tripathi, Shashwat, et al. “cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma.” F1000res, vol. 11, 2022, p. 1010. Pubmed, doi:10.12688/f1000research.125163.1.
URI
https://scholars.duke.edu/individual/pub1555262
PMID
36324813
Source
pubmed
Published In
F1000research
Volume
11
Published Date
Start Page
1010
DOI
10.12688/f1000research.125163.1
Rory David Deutsch Distinguished Professor of Neuro-Oncology
Contact:
203 Research Dr Msrb1, Box 2600, Durham, NC 27710
DUMC 2600, Durham, NC 27710